



## Amicus Therapeutics Announces Participation at the 2022 AANEM Annual Meeting

September 21, 2022

PHILADELPHIA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- [Amicus Therapeutics](#) (Nasdaq: FOLD), today announced three poster presentations highlighting its development program for Pompe disease will be included at the [2022 American Association of Neuromuscular & Electrodiagnostic Medicine \(AANEM\) Annual Meeting](#), being held September 21-24, 2022 in Nashville, TN and virtually.

### **Poster Presentations:**

- **Abstract Title:** *Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory patients with Pompe disease: an open-label Phase I/II study (ATB200-02) (Poster #104)*  
**Presenter:** Barry J. Byrne, MD, PhD, University of Florida, Gainesville, FL, U.S.A.  
**Date and Time:** Thursday, September 22, 6:00-6:30 p.m. CT and Friday, September 23, 3:30-4:00 p.m. CT  
**Location:** Ryman Exhibit Hall B1
- **Abstract Title:** *Immunogenicity of cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease: a Phase III, randomized study (PROPEL) (Poster #185)*  
**Presenter:** Sheela Sitaraman Das, PhD, Amicus Therapeutics Inc., Philadelphia, PA, U.S.A.  
**Date and Time:** Thursday, September 22, 6:00-6:30 p.m. CT and Friday, September 23, 9:30-10:00 a.m. CT  
**Location:** Ryman Exhibit Hall B1
- **Abstract Title:** *Mechanism of action, pharmacokinetic profiles, and pharmacokinetic/pharmacodynamic relationships differ between cipaglucosidase alfa/miglustat and alglucosidase alfa in late-onset Pompe disease (Poster #166)*  
**Presenter:** Franklin K. Johnson, PhD, Amicus Therapeutics Inc., Philadelphia, PA, U.S.A.  
**Date and Time:** Thursday, September 22, 6:00-6:30 p.m. CT and Friday, September 23, 9:30-10:00 a.m. CT  
**Location:** Ryman Exhibit Hall B1

The posters will be made available on the Amicus [website](#) following their respective presentations at the conference.

For more information on the 2022 AANEM Annual Meeting, please visit [www.aanem.org](http://www.aanem.org).

### **About Amicus Therapeutics**

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company's website at [www.amicusrx.com](http://www.amicusrx.com), and follow us on [Twitter](#) and [LinkedIn](#).

### CONTACTS:

#### **Investors:**

Amicus Therapeutics  
Andrew Faughnan  
Executive Director, Investor Relations  
[afaughnan@amicusrx.com](mailto:afaughnan@amicusrx.com)  
(609) 662-3809

#### **Media:**

Amicus Therapeutics  
Diana Moore  
Head of Global Corporate Communications  
[dmoore@amicusrx.com](mailto:dmoore@amicusrx.com)  
(609) 662-5079

FOLD-G